CRISPR Therapeutics AG (MEX:CRSPN) Cyclically Adjusted Revenue per Share: MXN54.17 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:CRSPN CRISPR Therapeutics AG MEX:CRSPN
41 GF Score
Price MXN920.00
GF Value MXN77.01
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Cyclically Adjusted Revenue per Share?

CRISPR Therapeutics AG MEX:CRSPN +1.10% 41 Cyclically Adjusted Revenue per Share is MXN54.17 as of Jun. 2026. GuruFocus rates MEX:CRSPN with a GF Score™ of 41/100 and a GF Value™ of MXN77.01 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

CRISPR Therapeutics AG's adjusted revenue per share for the three months ended in Jun. 2026 was MXN1.808. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN54.17 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-08), CRISPR Therapeutics AG's current stock price is MXN920.00. CRISPR Therapeutics AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN54.17. CRISPR Therapeutics AG's Cyclically Adjusted PS Ratio of today is 16.98.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of CRISPR Therapeutics AG was 19.32. The lowest was 14.96. And the median was 16.63.


CRISPR Therapeutics AG  (MEX:CRSPN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CRISPR Therapeutics AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=920.00/54.17
=16.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of CRISPR Therapeutics AG was 19.32. The lowest was 14.96. And the median was 16.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


CRISPR Therapeutics AG Cyclically Adjusted Revenue per Share Related Terms


CRISPR Therapeutics AG Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Cyclically Adjusted Revenue per Share Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CRISPR Therapeutics AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 57.36 54.17

MEX:CRSPN vs MANE, EWTX, CAI: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, CRISPR Therapeutics AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Cyclically Adjusted PS Ratio falls into.


MEX:CRSPN
41GF Score
CRISPR Therapeutics AG MEX:CRSPN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CRISPR Therapeutics AG's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.808/108.5600*108.5600
=1.808

Current CPI (Jun. 2026) = 108.5600.

CRISPR Therapeutics AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.754 99.604 0.822
201612 1.217 99.380 1.329
201703 1.281 100.040 1.390
201706 1.623 100.285 1.757
201709 1.081 100.254 1.171
201712 15.669 100.213 16.974
201803 0.538 100.836 0.579
201806 0.456 101.435 0.488
201809 0.222 101.246 0.238
201812 0.044 100.906 0.047
201903 0.122 101.571 0.130
201906 0.115 102.044 0.122
201909 72.638 101.396 77.770
201912 24.101 101.063 25.889
202003 0.060 101.048 0.064
202006 0.017 100.743 0.018
202009 0.047 100.585 0.051
202012 0.054 100.241 0.058
202103 0.055 100.800 0.059
202106 222.740 101.352 238.581
202109 0.089 101.533 0.095
202112 3.170 101.776 3.381
202203 0.046 103.205 0.048
202206 0.041 104.783 0.042
202209 0.024 104.835 0.025
202212 0.001 104.666 0.001
202303 22.910 106.245 23.409
202306 15.173 106.576 15.456
202309 0.000 106.570 0.000
202312 42.599 106.461 43.439
202403 0.000 107.355 0.000
202406 0.000 107.991 0.000
202409 0.000 107.468 0.000
202412 8.540 107.128 8.654
202503 0.000 107.722 0.000
202506 0.000 108.075 0.000
202509 0.000 107.710 0.000
202512 0.000 107.200 0.000
202603 0.188 108.060 0.189
202606 1.808 108.560 1.808

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN54.17 mean?
CRISPR Therapeutics AG (MEX:CRSPN) has a Cyclically Adjusted Revenue per Share of MXN54.17 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Cyclically Adjusted Revenue per Share too high?
CRISPR Therapeutics AG's current Cyclically Adjusted Revenue per Share is MXN54.17. Overall, CRISPR Therapeutics AG has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Cyclically Adjusted Revenue per Share compare to MANE and EWTX?
CRISPR Therapeutics AG's Cyclically Adjusted Revenue per Share of MXN54.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Cyclically Adjusted Revenue per Share is MXN54.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (MEX:CRSPN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN77.01, compared to a current price of MXN920.00 — trading 1094.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN54.17. CRISPR Therapeutics AG's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For CRISPR Therapeutics AG (MEX:CRSPN), the current Cyclically Adjusted Revenue per Share is MXN54.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (MEX:CRSPN) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of MXN920.00 is trading 1094.7% above its estimated GF Value™ of MXN77.01. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for MEX:CRSPN:

  • Cyclically Adjusted Revenue per Share: MXN54.17
  • GF Value™: MXN77.01 vs. price of MXN920.00 (1094.7% above fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the MEX:CRSPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score

Get the complete analysis for MEX:CRSPN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN920.00
Price
MXN77.01
GF Value